MAGE

IFNγ ELISPOT results with a median fold change with the addition of the TAA MAGE in R was 2.0-fold (Fig. 3A).

IFNγ ELISPOT results with a median fold change ... MAGE/anti-PD-1 3.0-fold (Fig. 3A).

In NR for MAGE the increase was 1.1-fold (Fig. 3B).

In NR ... MAGE/anti-PD-1 1.6-fold (Fig. 3B).

In the GrB ELISPOT we saw an increase in immune responses for MAGE ... for the R of 2.5 ... -fold (Fig. 3C).

In the GrB ELISPOT we saw an increase in immune responses for ... MAGE/anti-PD-1 for the R of ... 4.7-fold (Fig. 3C).

When considering the NR, fold change was 1.4 by MAGE stimulation (Fig. 3D).

When considering the NR, fold change was ... by MAGE and anti-PD-1 3.1 (Fig. 3D).

The IFNγ/GrB-ELISPOT results show in principle that LAG-3 has no effect either alone or in combination with anti-PD-1 (Fig. 4A).

The IFNγ/GrB-ELISPOT results show in principle that LAG-3 has no effect either alone or in combination with anti-PD-1 (Fig. 4B).

The same applies to TIM-3, which does not elicit an immune response either alone or in combination with anti-PD-1 (Fig. 4C).

The same applies to TIM-3, which does not elicit an immune response either alone or in combination with anti-PD-1 (Fig. 4D).

The MAGE pentamer as TAA showed, as expected, lower expression of CD8+/MAGE pentamer+ cells of a mean of 0.43%, n=3 HD (Fig. 2C).